

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
NOVEMBER 19, 2010**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

Progenics Pharmaceuticals, Inc.

File No. 000-23143 - CF# 25818

Progenics Pharmaceuticals, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-K/A filed on October 18, 2010.

Based on representations Progenics Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.34	through June 14, 2015
Exhibit 10.35	through October 17, 2020
Exhibit 10.36	through October 17, 2020

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Daniel S. Greenspan
Special Counsel